Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

Study ID Alternative Stable ID Type
phs000649 Prospective

Study Description

This is a prospective, multicenter, randomized, open-label, parallel-group study to evaluate pharmacogenomic responses to antihypertensives. The primary aim of this study is to identify the genetic determinants of antihypertensive and adverse metabolic responses focused on two preferred and pharmacodynamically contrasting drugs, a beta-blocker (atenolol) and a thiazide diuretic (HCTZ) given initially as monotherapy, and subsequently in combination, to 768 individuals with uncomplicated hypertension. This includes assessment of genetic associations with: antihypertensive responses to monotherapy, addition of a second drug to monotherapy, and combination therapy; and adverse metabolic responses to mono and combination therapy. High quality phenotype data, including both home and ambulatory measures of blood pressure response, and lipid and insulin sensitivity measures of adverse metabolic responses were collected. DNA samples were plated into 96-well plates and included a 2% sample replication for QC and a Caucasian parent-child CEPH trio from the HapMap project to check for ... (Show More)

Archive Link Archive Accession
dbGaP phs000649

Who archives the data?

There are no publications available